StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Leqvio Global Growth in Constant Currencies by Year

Leqvio Global Growth in Constant Currencies (% cc) (%)

Novartis Leqvio Global Growth in Constant Currencies: 57.0% in FY2025, down 57.0 pts from a year earlier.

Latest, FY2025
57.0%
Period ended Dec 31, 2025
Change on a year earlier
-57.0 pts
114.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Leqvio | 1 198 | 754 | 59 | 57”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLeqvio Global Growth in Constant Currencies (% cc) (%)Year on yearSource
FY2025Dec 31, 202557.0%-57.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 2024114.0%-103.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 2023217.0%–Novartis Form 6-K (0001370368-24-000007) ↗

Cite this data

StockData. (2026). Novartis Leqvio Global Growth in Constant Currencies (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-leqvio-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.